Continuing Education Activity
Ductal carcinoma in situ (DCIS) of the breast represents neoplastic lesions, typically localized to the breast ducts with no evidence of invasion into the surrounding tissue. The diagnosis of DCIS has significantly increased in the recent past since the implementation of routine screening mammograms. Therapeutic approaches include surgery, radiation therapy, and adjuvant endocrine therapy. This activity reviews the evaluation and treatment of DCIS and highlights the healthcare team's role in managing patients with DCIS.
- Review the epidemiology of ductal carcinoma in situ.
- Summarize the evaluation of ductal carcinoma in situ.
- Identify the management options available for ductal carcinoma in situ.
- Outline some interprofessional team strategies that can improve outcomes for patients who require ductal carcinoma in situ.
Ductal carcinoma in situ (DCIS), also referred to as intraductal carcinoma, is a non-invasive breast cancer characterized by a proliferation of abnormal epithelial cells confined within the basement membrane. Disruption of the basement membrane layer would change the diagnosis from DCIS to invasive breast cancer. DCIS is considered to be a precursor for invasive breast cancer. Specifically, the World Health Organization defines the term DCIS as "a neoplastic proliferation of epithelial cells confined to the mammary ductal-lobular system and characterized by subtle to marked cytologic atypia and an inherent but not necessarily obligate tendency to progression to invasive breast cancer."
Although grouped, DCIS is, in reality, a heterogeneous group of lesions that varies in the clinical presentation, genetics, biomarkers, morphologic features, as well as the clinical potential to progress to invasive breast cancer. Rates of diagnosis have been increasing with the use of screening mammography that detects pre-clinical microcalcifications. However, the diagnosis of DCIS does require a tissue biopsy. The treatment for DCIS is multidisciplinary and may include surgery, hormone therapy, and radiation therapy.
The evolution of normal breast tissue to ductal carcinoma in situ is unknown. There is a genetic predisposition in some but not all patients with DCIS, most notably BRCA1 and BRCA2 mutations.
Overall, breast cancer is the most common cancer in women in the United States. In women aged 50 to 64 years of age, the risk of ductal carcinoma in situ is as high as 88 per 100,000 women. Today, 20% to 25% of breast cancer diagnosed in the United States is DCIS. This has increased concurrently with the use of screening mammography, as a significant percentage of DCIS is first identified on screening mammography. In the pre-screening mammography era, less than 5% of newly diagnosed breast cancers were DCIS.
A recent 2020 NCI-funded study modeled the natural history of DCIS using a combination of two population models and six submodels. They found that 36% to 100% of DCIS progressed to invasive breast cancer without surgical excision or treatment, with a mean progression time of 0.2 to 2.5 years. DCIS overdiagnosis ranged from 3.1% to 65.8%. They concluded that the majority of DCIS would progress to invasive breast cancer. However, the wide variation has to do with the heterogeneity and subtype variation within DCIS, and that more study needs to be done for various subtypes.
Other risk factors contribute to the progression of DCIS to invasive breast cancer. As a woman ages from birth to death, the probability of developing invasive breast cancer is 12.3% or 1 in 8. Increased exposure to estrogen can also increase the risk of developing breast cancer. The use of hormone replacement therapy in postmenopausal women has been associated with an increased risk of breast cancer. Additionally, a high endogenous level of estrogen increases the risk of breast cancer; this can be approximated by age at first menarche, age at menopause, and age at first live birth. Alcohol use is associated with an increased risk of breast cancer as well. Patients with first degree relatives with breast cancer are at a higher risk of breast cancer.
Ductal carcinoma in situ is one of two general categories of in-situ neoplasms of the breast, the other being lobular carcinoma in situ (LCIS). DCIS is characterized and defined by a proliferation of abnormal epithelial cells that are confined within the basement membrane. Complete confinement within the basement membrane is what delineates DCIS from invasive breast cancer.
DCIS is somewhat heterogeneous as it can be further broken down into four main types: papillary, solid, cribriform, and comedo. In cribriform type DCIS, pathology reveals tumor cells that bridge and that span the ductal space and leave round, punched-out gaps. In comedo type DCIS, the malignant cells in the center of the lesion undergo necrosis with coagulation and calcification. The four histologic types are often mixed and rarely found as pure lesions, but are helpful for determining risk for transformation into a higher grade or invasive cancer. Of the four types, the papillary and cribriform types are lower grade whereas the solid and comedo types are higher-grade lesions.
History and Physical
A thorough history and physical exam should be included in all breast patients, and ductal carcinoma in situ is no exception. Regardless of their chief complaint, all breast patients will need the same baseline information, including the following: age at menarche, number of pregnancies, number of live births, age at first birth, family history of breast cancer, family history of cancer, history of breast biopsies, alcohol use, duration of use of hormone replacement therapy for postmenopausal women, and use of oral contraception for the premenopausal woman. Any patient identified as a high risk for hereditary breast cancer after taking a detailed family history of cancer should be offered genetic counseling.
A detailed physical exam is important, as well. Although patients may not have any palpable masses, it is important to perform a physical exam that carefully evaluates breasts and axillae bilaterally for nipple discharge, skin changes, lumps, discharge, and lymphadenopathy when the patients present for evaluation. Many women present for a breast examination after an abnormality have been found on screening mammograms. There may be a range of physical exam findings from obvious changes in the physical exam to no external breast changes noticeable.
Ductal carcinoma in situ most commonly presents without a palpable mass and is most commonly found via screening mammograms. Ninety percent of all cases of DCIS are detected from screening mammograms. Additionally, if the patient was referred with a suspicious lesion on screening mammography, it is important to perform diagnostic mammography to characterize the ipsilateral disease and rule out bilateral disease. A screening mammogram consists of two views of the breast, and it is sensitive but not specific for breast malignancy. On mammograms, presentation of clustered macrocalcification is common for DCIS. Calcifications associated with malignancy tend to be smaller in size (0.1 to 1 mm in diameter) and are usually clustered. Microcalcifications that appear in linear branching patterns or segmental types of pleomorphic calcifications are highly suspicious for DCIS. Once suspicious calcifications are identified on screening mammography, it is important to proceed with diagnostic mammography, including additional cuts and information that is important for surgical planning.
Image-guided core needle biopsy performed on the area of suspicion will provide a histologic diagnosis. Core needle biopsy will allow for more tissue to be sampled compared to fine-needle aspiration; this will allow the pathologist to determine if breast cancer is invasive or noninvasive (DCIS). Classically, DCIS has been classified architecturally as comedo, cribriform, micropapillary, papillary, or solid. Of note, even core needle biopsy has limitations. when core needle biopsy reveals DCIS, there is still a 10% to 20% chance that the final excisional surgical specimen will contain invasive carcinoma.
Tissue biopsy should also be evaluated for hormone receptor status - particularly estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) status. Although other receptors are being identified and studied, these three receptors are important to identify. There are specific endocrine treatment modalities that can be given to further reduce risk in patients with ER/PR/HER-2 receptor positivity.
With a positive diagnosis of DCIS, the patient will need to proceed to surgery for either breast conservation surgery or total mastectomy. Determination is made based on history and physical exam findings that are important to obtain during the initial evaluation. Cosmesis and the size of the lesion should be taken into consideration. Multifocal, multicentric disease and large lesion size may make breast conservation surgery a less cosmetic option than mastectomy. One must determine if the patient is suitable for breast conservation by evaluation if the patient has a contraindication to post-surgical radiation therapy, such as pregnancy or previous radiation therapy. Information regarding the patient's preferences and ability to follow-up for subsequent treatments with radiation therapy should also be elicited.
Additionally, it should be determined on evaluation if the patient needs a referral for genetic counseling. This is determined by a careful personal and family history that uncovers higher than expected breast and other cancer rates, particularly at young ages. These patients may decide to forgo breast conservation therapy for mastectomy if they discover they have a genetic predisposition to developing breast cancer.
Treatment / Management
Treatment for ductal carcinoma in situ is multimodal and involves a combination of surgery, radiation therapy, and hormone therapy that is personalized to the patient's specific diagnosis and preferences.
Surgical treatment options for DCIS broadly include breast-conserving surgery followed by radiation or a simple mastectomy. With either treatment option, it is important to emphasize that there is equivalent long-term survival. Breast-conserving treatment (BCT) with partial mastectomy and radiation is generally recommended since it is a less surgically invasive procedure. BCT is contraindicated in patients with multicentric disease, an extensive disease where there will not be enough remaining breast tissue for cosmesis, and in patients who cannot receive radiation therapy. Mastectomy is curative in 98% of patients with DCIS who undergo it regardless of tumor size or grade.
DCIS, by definition, is noninvasive, and axillary lymph node involvement in DCIS is rare; thus, sentinel lymph node (SLN) biopsy is not indicated during breast-conserving surgery. Data from the NSABP B24 trials demonstrate that axillary recurrence rates irrespective of treatment (BCT vs. mastectomy) were 0.36 per 1000 patient-years of follow up. For patients undergoing mastectomy for DCIS, an SLN biopsy should be considered since an occult invasive breast cancer could be identified, and an SLN biopsy is often not possible after a mastectomy.
Medical management of DCIS consists primarily of endocrine therapy in patients with ER-positive or PR-positive DCIS. It is well supported by the data that 5 years of endocrine therapy in the appropriate patient does reduce the risk of both ipsilateral and contralateral disease. There is some thought that treating HER-2 positive patients with trastuzumab may be beneficial as well, and data available from a 2020 NRG Oncology/NSABP B-43 protocol presented at a meeting of the American Society of Clinical Oncology (ASCO) suggest a possible benefit, but differences so far are not statistically significant and more research needs to be done.
It is important to be aware that if a patient has ductal carcinoma in situ, there is a real risk the patient already has invasive breast cancer. Approximately 10% to 20% of DCIS lesions diagnosed on core needle biopsy will be upgraded to invasive cancer after definitive resection; furthermore, large high-grade DCIS lesions have a higher likelihood of containing an invasive component.
The surgical approach to ductal carcinoma in situ is broadly categorized into two categories: 1) breast conservation and 2) mastectomy. In this section, we will discuss the surgical approach to both.
For breast conservation, the first step is pre-surgical localization of the lesion as many of these lesions are non-palpable and only seen on imaging. This can be done by wire localization immediately pre-procedure or wireless radioactive seed, which can be placed in the days prior to surgery. Both have comparable outcomes when it comes to localizing the lesion with negative margins.
Surgical planning should also involve reviewing pre-operative imaging to plan the depth and location of mass to make the appropriate incision and resection, taking into account safety, efficiency, and cosmesis.
The lesion should be excised without entering into the specimen or damaging it with excessive electrocautery or other undue force. A thin buffer of normal breast tissue should be left with the specimen to ensure a 2 mm negative margin on final pathology. Once removed, the specimen should be tagged and oriented in three-dimensional space using ink or marking suture. Intraoperative X-ray imaging should be performed of the specimen to confirm an intact wire, microclip, seed, and lesion (if the latter is visible on X-ray). After radiologic confirmation of satisfactory biopsy, the area of tissue resection should be inspected and palpated to ensure no other area of concerning tissue warrants resection. Data support a lower risk of positive margins, reoperation, and mastectomy when the surgeon takes additional margins during the index operation in the setting of suspected residual abnormal tissue. Clips should be placed to mark the borders of the lumpectomy site for radiation planning. Care should be taken to ensure hemostasis is achieved before closure.
Post-operatively, the patient will need to undergo radiation therapy. Before initiating radiation therapy, the patient will need pathologic and radiologic confirmation of negative margins from surgery, or a re-operation for additional tissue excision will need to take place. This requires negative margins of 2 mm. It also requires a mammogram 1 to 3 weeks after surgery but before initiating radiation therapy to confirm complete excision. Six months after completion of radiation therapy, surveillance mammography should be initiated with yearly imaging. Biannual bilateral breast and lymph node exams are indicated for two years, and then annually thereafter.
After completing radiation therapy, the patient may consider referral to a plastic or breast oncologic surgeon for oncoplastic reconstruction options.
For mastectomy, there is no pre-procedural need to localize the lesion. However, sentinel lymph node biopsy is recommended along with mastectomy due to the inability to perform sentinel lymph node biopsy after mastectomy should the lesion be upgraded on final pathology to invasive breast cancer. Surgical planning should consider post-mastectomy plans for reconstruction and cosmesis, particularly in terms of planning a skin-sparing mastectomy, a nipple-sparing mastectomy, the incision choice, and the possible placement of tissue expanders. Therefore, after surgical planning, the first pre-operative step is sentinel lymph node mapping with a radioisotope and/or blue dye (methylene blue, lymphazurin, etc.).
Simple mastectomy dissection should be made superiorly to the clavicle, medially to the sternum, inferiorly to the anterior rectus sheath, laterally to the latissimus dorsi, and posteriorly to the pectoralis muscle, making sure to include the pectoralis fascia in the specimen.
Ipsilateral sentinel lymph node biopsy should then be performed, ideally utilizing the same incision. Again, hemostasis should be obtained. A drain or two should be placed within the mastectomy site. Post-operatively, drains are removed once drain output is less than around 30mL in a 24 hour period.
Post-operatively, once the patient has healed from mastectomy and pathology results have been reviewed, the patient may plan for breast reconstruction surgery.
Although imaging of the removed breast is not needed for surveillance, the contralateral breast should undergo yearly mammograms. Biannual bilateral breast and lymph node exams are indicated for two years, and then annually thereafter.
After obtaining negative margins in partial mastectomy, radiation will follow to eliminate any residual disease. The NSABP B17 trial demonstrated that in patients who underwent breast-conserving surgery and were followed with radiation, there is a 50 to 60% reduction in local recurrence with surgical excision and radiation therapy compared to surgical excision alone. Typically, patients will undergo whole breast radiation with a total dose of 50 to 60 Gy after breast-conserving therapy. Patients will have radiation treatment 5 days a week with 2 Gy fractions of radiation for a total of 5 weeks after the partial mastectomy. The goal is to reduce the risk of locoregional recurrence the following surgery by eradicating any persistent locoregional disease.
It is important to recognize medical contraindications for radiation therapy, including pregnancy, previous radiation therapy, and a pacemaker in the radiotherapy field. Other conditions that in severe cases are a contraindication include severe pre-existing lung disease that substantially reduces diffusing capacity and connective tissue disorders (scleroderma, systemic lupus erythematosus, etc.) with significant vasculitis.
Social considerations should be taken into account. The scheduling burden of radiation therapy may not be feasible in patients who lack health care access due to insurance or poverty reasons (cannot afford a ride to the hospital, etc.), or rural location.
Chemotherapy is not indicated in patients with ductal carcinoma in situ after surgical treatment. However, medical endocrine therapy is a large component of the recommended treatment for DCIS. DCIS is staged as Tis and is Stage 0 breast cancer. Endocrine therapy is recommended if the DCIS specimen express estrogen and/or progesterone receptors. Tamoxifen has been demonstrated to prevent breast cancer recurrences in women with DCIS. In the NSABP B 24 trials, women with ER-positive DCIS treated with tamoxifen had significant decreases in any subsequent breast cancer events when given over five years post-diagnosis. This risk reduction is applied to both the ipsilateral and contralateral breast. Interestingly, despite proven reduction for breast cancer recurrences, there is no evidence of survival advantage with endocrine therapy. Therefore, in women who have undergone bilateral mastectomies, the risks of tamoxifen are likely to outweigh the benefits. Tamoxifen is known to increase the risk of endometrial cancer, stroke, deep vein thrombosis, pulmonary embolism; therefore, prior to initiating treatment, a thorough risk-benefit analysis should be undertaken with the patient.
There is some thought that treating HER-2 positive patients with trastuzumab may be beneficial as well, and data available from a 2020 NRG Oncology/NSABP B-43 protocol presented at a meeting of the American Society of Clinical Oncology (ASCO) suggest a possible benefit, but differences so far are not statistically significant and more research needs to be done. This is an area that is actively being researched, with new receptors and targeted therapy being developed and studied.
Given the noninvasive nature of ductal carcinoma in situ, metastases and/or death in women with DCIS who are treated are rare. If untreated, however, DCIS usually transforms into invasive cancer that may be deadly.
There is an excellent prognosis with a normal life expectancy for the vast majority of patients with DCIS who undergo treatment. However, there is still an increased breast cancer mortality with the diagnosis of DCIS. In a recent 2020 study published in JAMA Oncology of over 100,000 patients diagnosed with DCIS, the overall death rate from breast cancer at 20 years after diagnosis was 3.3%, a rate treble that of the general population. That rate was the same with either breast conservation therapy or mastectomy. Interestingly, the same study found the prevention of invasive in-breast recurrence with either radiotherapy or mastectomy did not reduce breast cancer-specific mortality.
A recent meta-analysis from 2019 identified six factors that were linked to a higher risk of recurrence of invasive breast cancer. These factors are DCIS found by a doctor during a physical exam, being premenopausal, positive margins, high-grade DCIS, high levels of p16 protein, and having African American ethnicity. While these results need to be validated by future studies, it highlights that DCIS is heterogeneous. In the future, differentiating between DCIS type and risk factors will help guide prognosis and eventually treatment to avoid both under and overtreatment.
Complications vary in severity and frequency and can occur in all stages of treatment.
Surgical complications include infection, hematoma, seroma, wound dehiscence, pain, lymphedema, pneumothorax (from wire placement), post-operative flap necrosis (skin flaps too thin), inadequate surgical margins requiring re-excision (skin flaps too thick or poor localization).
Positive margins after breast conservation surgery have been reported to range from 20% to 70%. A 2016 study reviewed 567 cases to identify risk factors that lead to positive margins and found that the use of multiple localizing needles for large lesions, also known as bracketing, resulted in a 2 to 3 fold increased risk of positive margins. The study authors also concluded that intraoperative resection of additional margins during the index surgery resulted in decreased positive margins on final pathology.
Another surgical complication causing patient dissatisfaction is a poor cosmetic outcome. This can be addressed preemptively at the index surgery by utilizing oncoplastic techniques or afterward in an additional operation.
Medical complications from hormone therapy with Tamoxifen include endometrial cancer, stroke, deep vein thrombosis, and pulmonary embolism.
Complications from radiation therapy include skin and tissue changes (firmer, smaller, discoloration, etc.), fatigue, cough, shortness of breath, rib fractures, and very rarely angiosarcoma and brachial plexopathy.
Deterrence and Patient Education
Understanding that increasing levels of exogenous estrogen increases the risk of breast cancer is important in patient education. Lifestyle and behavioral modifications such as stopping the use of postmenopausal hormones as well as alcohol use can decrease a woman's breast cancer risk.
Enhancing Healthcare Team Outcomes
Ductal carcinoma in situ treatment is multifaceted and should be tailored to the patient based on pathology, overall health, comorbidities, age, genetics, cosmetic concerns, hormone receptor status, medical access, social support, and patient preference. It is, therefore paramount for the physician to have a careful discussion with the patient in order to come to an informed decision in regards to the treatment plan and ensure care coordination for each patient. [Level 1] These patients will need coordination with some or all of the following specialties:
- General surgery/breast surgical oncology
- Medical genetics
- Plastic surgery
- Radiation oncology
- Internal medicine/medical oncology
Improved compliance with overall treatment plans in vulnerable populations can be achieved with care coordination utilizing case managers, social workers, and home health aides who are crucial for improving access to care. [Level 2]